Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review

Detalhes bibliográficos
Autor(a) principal: Matos, Pedro Henrique de
Data de Publicação: 2022
Outros Autores: Silva, Thalita Prates da, Mansano, Amanda Benites, Gancedo, Naiara Cássia, Tonin, Fernanda, Pelloso, Fernando Castilho, Petruco, Marcus Vinicius, Melo, Eduardo Borges de, Fernandez-Llimos, Fernando, Sanches, Andreia Cristina Conegero, Mello, João Carlos Palazzo de, Chierrito, Danielly, Araújo, Daniela Cristina de Medeiros
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.21/15080
Resumo: Objective and design: The current study aimed to summarize the evidence of compounds contained in plant species with the ability to block the angiotensin-converting enzyme 2 (ACE-II), through a scoping review. Methods: PubMed and Scopus electronic databases were used for the systematic search and a manual search was performed RESULTS: Studies included were characterized as in silico. Among the 200 studies retrieved, 139 studies were listed after the exclusion of duplicates, and 74 were included for the full read. Among them, 32 studies were considered eligible for the qualitative synthesis. The most evaluated class of secondary metabolites was flavonoids with quercetin and curcumin as most actives substances and terpenes (isothymol, limonin, curcumenol, anabsinthin, and artemisinin). Other classes also evaluated were alkaloid, saponin, quinone, substances found in essential oils, and primary metabolites such as the aminoacid L-tyrosine and the lipidic compound 2-monolinolenin. Conclusion: This review suggests the most active substance from each class of metabolites, which presented the strongest affinity to the ACE-II receptor, which contributes as a basis for choosing compounds and directing further experimental and clinical investigation on the applications these compounds in biotechnological and health processes as in COVID-19 pandemic.
id RCAP_7e4f50a896c060d482b1cd98f24e21af
oai_identifier_str oai:repositorio.ipl.pt:10400.21/15080
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping reviewACE-IICoronavirusSecondary metaboliteTreatmentObjective and design: The current study aimed to summarize the evidence of compounds contained in plant species with the ability to block the angiotensin-converting enzyme 2 (ACE-II), through a scoping review. Methods: PubMed and Scopus electronic databases were used for the systematic search and a manual search was performed RESULTS: Studies included were characterized as in silico. Among the 200 studies retrieved, 139 studies were listed after the exclusion of duplicates, and 74 were included for the full read. Among them, 32 studies were considered eligible for the qualitative synthesis. The most evaluated class of secondary metabolites was flavonoids with quercetin and curcumin as most actives substances and terpenes (isothymol, limonin, curcumenol, anabsinthin, and artemisinin). Other classes also evaluated were alkaloid, saponin, quinone, substances found in essential oils, and primary metabolites such as the aminoacid L-tyrosine and the lipidic compound 2-monolinolenin. Conclusion: This review suggests the most active substance from each class of metabolites, which presented the strongest affinity to the ACE-II receptor, which contributes as a basis for choosing compounds and directing further experimental and clinical investigation on the applications these compounds in biotechnological and health processes as in COVID-19 pandemic.Springer NatureRCIPLMatos, Pedro Henrique deSilva, Thalita Prates daMansano, Amanda BenitesGancedo, Naiara CássiaTonin, FernandaPelloso, Fernando CastilhoPetruco, Marcus ViniciusMelo, Eduardo Borges deFernandez-Llimos, FernandoSanches, Andreia Cristina ConegeroMello, João Carlos Palazzo deChierrito, DaniellyAraújo, Daniela Cristina de Medeiros2022-11-08T17:10:42Z2022-122022-12-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.21/15080engMatos PH, Silva TP, Mansano AB, Gancedo NC, Tonin FS, Castilho Pelloso F, et al. Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review. Inflamm Res. 2022;71(12):1489-500.10.1007/s00011-022-01642-7info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-08-03T10:12:09Zoai:repositorio.ipl.pt:10400.21/15080Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:22:48.876708Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review
title Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review
spellingShingle Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review
Matos, Pedro Henrique de
ACE-II
Coronavirus
Secondary metabolite
Treatment
title_short Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review
title_full Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review
title_fullStr Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review
title_full_unstemmed Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review
title_sort Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review
author Matos, Pedro Henrique de
author_facet Matos, Pedro Henrique de
Silva, Thalita Prates da
Mansano, Amanda Benites
Gancedo, Naiara Cássia
Tonin, Fernanda
Pelloso, Fernando Castilho
Petruco, Marcus Vinicius
Melo, Eduardo Borges de
Fernandez-Llimos, Fernando
Sanches, Andreia Cristina Conegero
Mello, João Carlos Palazzo de
Chierrito, Danielly
Araújo, Daniela Cristina de Medeiros
author_role author
author2 Silva, Thalita Prates da
Mansano, Amanda Benites
Gancedo, Naiara Cássia
Tonin, Fernanda
Pelloso, Fernando Castilho
Petruco, Marcus Vinicius
Melo, Eduardo Borges de
Fernandez-Llimos, Fernando
Sanches, Andreia Cristina Conegero
Mello, João Carlos Palazzo de
Chierrito, Danielly
Araújo, Daniela Cristina de Medeiros
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv RCIPL
dc.contributor.author.fl_str_mv Matos, Pedro Henrique de
Silva, Thalita Prates da
Mansano, Amanda Benites
Gancedo, Naiara Cássia
Tonin, Fernanda
Pelloso, Fernando Castilho
Petruco, Marcus Vinicius
Melo, Eduardo Borges de
Fernandez-Llimos, Fernando
Sanches, Andreia Cristina Conegero
Mello, João Carlos Palazzo de
Chierrito, Danielly
Araújo, Daniela Cristina de Medeiros
dc.subject.por.fl_str_mv ACE-II
Coronavirus
Secondary metabolite
Treatment
topic ACE-II
Coronavirus
Secondary metabolite
Treatment
description Objective and design: The current study aimed to summarize the evidence of compounds contained in plant species with the ability to block the angiotensin-converting enzyme 2 (ACE-II), through a scoping review. Methods: PubMed and Scopus electronic databases were used for the systematic search and a manual search was performed RESULTS: Studies included were characterized as in silico. Among the 200 studies retrieved, 139 studies were listed after the exclusion of duplicates, and 74 were included for the full read. Among them, 32 studies were considered eligible for the qualitative synthesis. The most evaluated class of secondary metabolites was flavonoids with quercetin and curcumin as most actives substances and terpenes (isothymol, limonin, curcumenol, anabsinthin, and artemisinin). Other classes also evaluated were alkaloid, saponin, quinone, substances found in essential oils, and primary metabolites such as the aminoacid L-tyrosine and the lipidic compound 2-monolinolenin. Conclusion: This review suggests the most active substance from each class of metabolites, which presented the strongest affinity to the ACE-II receptor, which contributes as a basis for choosing compounds and directing further experimental and clinical investigation on the applications these compounds in biotechnological and health processes as in COVID-19 pandemic.
publishDate 2022
dc.date.none.fl_str_mv 2022-11-08T17:10:42Z
2022-12
2022-12-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.21/15080
url http://hdl.handle.net/10400.21/15080
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Matos PH, Silva TP, Mansano AB, Gancedo NC, Tonin FS, Castilho Pelloso F, et al. Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review. Inflamm Res. 2022;71(12):1489-500.
10.1007/s00011-022-01642-7
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer Nature
publisher.none.fl_str_mv Springer Nature
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799133500522102784